Development of federally mandated risk evaluation and mitigation strategies (REMS) for transmucosal immediate-release fentanyl products

Pain Pract. 2013 Apr;13(4):259-63. doi: 10.1111/papr.12040. Epub 2013 Mar 6.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Mucosal
  • Analgesics, Opioid / administration & dosage*
  • Fentanyl / administration & dosage*
  • Humans
  • Pain / drug therapy*
  • Pharmacovigilance*
  • Risk Management / methods*
  • United States

Substances

  • Analgesics, Opioid
  • Fentanyl